The 5 lipoxygenase system in the vasculature: Emerging role in health and disease

Molecular and Cellular Endocrinology

Volumn 252, Issue 1-2, 2006, Pages 201-206

  Osher, Etty ^a   Weisinger, Gary ^a   Limor, Rona ^a   Tordjman, Karen ^a   Stern, Naftali ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

5 Lipoxygenase; Cysteinyl leukotrienes; Leukotrienes; Vascular cells

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ICOSANOID; LEUKOTRIENE; LEUKOTRIENE RECEPTOR;

ARTICLE; ATHEROSCLEROSIS; BIOSYNTHESIS; ENZYME REGULATION; HUMAN; METABOLITE; OXIDATIVE STRESS; PRIORITY JOURNAL; VASCULARIZATION;

ARACHIDONATE 5-LIPOXYGENASE; BLOOD VESSELS; EICOSANOIDS; ENDOTHELIUM, VASCULAR; HUMANS; MACROPHAGES; MUSCLE, SMOOTH, VASCULAR; OXIDATIVE STRESS; RECEPTORS, LEUKOTRIENE;

EID: 33745190052     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2006.03.038     Document Type: Article

References (45)

1. Aiello R.J., Bourassa P.A., Lindsey S., Weng W., Freeman A., and Showell H.J. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 443-449
2. Allen S., Dashwood M., Morrison K., and Yacoub M.H. Differential leukotriene constrictor responses in human atherosclerptic coronary arteries. Circulation 97 (1998) 2406-2413
3. Allen S.P., Chester A.H., Dashwood M..R., Tadjkarimi S., Piper P.J., and Yacoub M.H. Preferential vasoconstriction to cysteinyl leukotrienes in the human saphenous vein compared with the internal mammary artery. Implication for graft performance. Circulation 90 (1994) 515-524
4. Berkowitz B.A., Zabko-Potapovich B., Valocik R., and Gleason J.G. Effects of the leukotrienes on the vasculature and blood pressure of different species. J. Pharmacol. Exp. Ther. 229 (1984) 105-112
5. Buccellati C., Rossoni G., Bonazzi A., Berti F., Maclouf J., Folco G., and Sala A. Nitric oxide modulation of transcellular biosynthesis of cys-leukotrienes in rabbit leukocyte-perfused heart. Brit. J. Pharmacol. 120 (1997) 1128-1134
6. Byrum R.S., Goulet J.L., Snouwaert J.N., Griffiths R.J., and Koller B.H. Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase and leukotriene A4 hydrolase-deficient mice. J. Immunol. 163 (1999) 6810-6819
7. Cipollone F., Mezzetti A., Fazia M., Cuccurullo C., Lazzi A., Ucchino S., Spigonardo F., Bucci M., Cuccurullo F., Prescott S.M., and Stafforini D.M. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1665-1670
8. Dwyer J.H., Allayee H., Dwyer K.M., Fan J., Wu H., Mar R., Lusis A.J., and Mehrabian M. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N. Engl. J. Med. 1 350 (2004) 29-37
9. Fiorucci S., Distrutti E., Mencarelli A., Morelli A., Laufor S.A., Cirino G., and Wallace J.L. Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. Brit. J. Pharmacol. 139 (2003) 1351-1359
10. Fujioka H., Ayajiki K., Shinozaki K., Toda N., and Okamura T. Mechanisms underlying endothelium-dependent, nitric oxide- and prostanoid-independent relaxation in monkey and dog coronary arteries. Naunyn. Schmiedebergs. Arch. Pharmacol. 366 (2002) 488-495
11. Hakonarson H., Thorvaldsson S., Helgadottir A., Gudbjartsson D., Zink F., Manolescu M.A., Arner D.O., Andersen K., Sigurdsson A., Thorgeirsson G., Jonsson A., Agnarsson U., Bjornsdottir H., Gottskalksson G., Einarsson A., Gudmundsdottir H., Adalsteinsdottir A.E., Gudmundsson K., Kristjansson K., Hardarson T., Kristinsson A., Topol E.J., Gulcher J., Kong A., Gurney M., Thorgeirsson G., and Stefansson K. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 293 (2005) 2245-2256
12. Hammarberg T., Provost P., Persson B., and Rådmark O. The N-terminal domain of 5-lipoxygenase binds calcium and mediates calcium stimulation of enzyme activity. J. Biol. Chem. (2000) 38787-38793
13. Hardy G., Stanke-Labesque F., Peoc'h M., Hakim A., Devillier P., Caron F., Morel S., Faure P., Halimi S., and Bessard G. Cysteinyl leukotrienes modulate angiotensin II constrictor effects on aortas from streptozotocin-induced diabetic rats. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1751-1758
14. Helgadottir A., Manolescu A., Thorleifsson G., Gretarsdottir S., Jonsdottir H., Thorsteinsdottir U., Samani N.J., Gudmundsson G., Grant S.F., Thorgeirsson G., Sveinbjornsdottir S., Valdimarsson E.M., Matthiasson S.E., Johannsson H., Gudmundsdottir O., Gurney M.E., Sainz J., Thorhallsdottir M., Andresdottir M., Frigge M.L., Topol E.J., Kong A., Gudnason V., Hakonarson H., Gulcher J.R., and Stefansson K. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet. 36 (2004) 233-239
15. Helgadottir A., Gretarsdottir S., St. Clair D., Manolescu A., Cheung J., Thorleifsson G., Pasdar A., Grant S.F.A., Whalley L.J., Hakonarson H., Thorsteinsdottir U., Kong A., Gulcher J., Stefansson K., and MacLeod M.J. Association between the gene encoding 5-lipoxygenase activating protein and stroke replicated in a Scottish population. Am. J. Hum. Genet. 76 (2005) 505-509
16. Heller E.A., Liu E., Tager A.M., Sinha S., Roberts J.D., Koehn S.L., Libby P., Aikawa E.R., Chen J.Q., Huang P., Freeman M.W., Moore K.J., Luster A.D., and Gerszten R.E. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 112 (2005) 578-586
17. Labat C., Oritz J.Z., Norel X., Gorenne I., Verley J., Abram T.S., Cuthbert N.J., Tudhope S.R., Norman P., and Gardiner P. A second cysteinyl leukotriene receptor in human lung. J. Pharmacol. Exp. Ther. 263 (1992) 800-805
18. Lawson D.L., Mehta J.L., Mehta P., and Nichols W.W. Endothelium-dependent relaxation of rat aortic rings by leukotriene D4: importance of the magnitude of preload. Eicosanoids 2 (1989) 175-181
19. Lõhmussaar E., Gschwendtner A., Mueller J.C., Org T., Wichmann E., Hamann G., Meitinger T., and Dichgans M. ALOX5AP gene and the PDE4D gene in a central European stroke patients. Stroke 36 (2005) M.731-M.736
20. Lotzer K., Spanbroek R., Hildner M., Urbach A., Heller R., Bretschneider E., Galczenski H., Evans J.F., and Habenicht A.J. Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 23 (2003) e32-e36
21. Luchtefeld M., Drexler H., and Schieffer B. 5-Lipoxygenase is involved in the angiotensin II-induced NAD(P)H-oxidase activation. Biochem. Biophys. Res. Commun. 308 (2003) 668-672
22. Martel-Pelletier J., Lajeunesse D., Reboul P., and Pelletier J.P. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann. Rheum. Dis. 62 (2003) 501-509
23. Mazzetti L., Franchi-Micheli S., Nistri S., Quattrone S., Simone R., Ciuffi M., Zilletti L., and Failli P. The ACh-induced contraction in rat aortas is mediated by the Cys Lt1 receptor via intracellular calcium mobilization in smooth muscle cells. Brit. J. Pharmacol. 138 (2003) 707-715
24. Mehrabian M., Allayee H., Wong J., Shi W., Wang X.P., Shaposhnik Z., Funk C.D., Lusis A.J., and Shih W. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ. Res. 91 (2002) 120-126
25. Norel X., and Brink C. The quest for new cysteinyl-leukotriene and lipoxin receptors: recent clues. Pharmacol. Ther. 103 (2004) 81-94
26. O'Flaherty J.T., and Rossi A.G. 5-Hydroxyicosatetraenoate stimulates neutrophils by a stereospecific, G protein-linked mechanism. J. Biol. Chem. 268 (1993) 14708-14714
27. Phare M.J., Coffey M., and Peters-Golden Brock T.G. Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. J. Biol. Chem. 279 (2004) 41512-41520
28. Radmark O.P. The molecular biology and regulation of 5-lipoxygenase. Am. J. Respir. Crit. Care Med. 161 (2000) S11-S15
29. Rocha P.N., Plumb T.J., and Coffman T.M. Eicosanoids: lipid mediators of inflammation in transplantation. Semin. Immunopathol. 25 (2003) 215-227
30. Shastri S., McNeill J.R., Wilson T.W., Poduri R., Kaul C., and Gopalakrishnan V. Cysteinyl leukotrienes mediate enhanced vasoconstriction to angiotensin II but not endothelin-1 in SHR. Am. J. Physiol. Heart Circ. Physiol. 281 (2001) H342-H349
31. Sjostrom M., Jakobsson P.J., Heimburger M., Palmblad J., and Haeggstrom J.Z. Human umbilical vein endothelial cells generate leukotriene C4 via microsomal glutathione S-transferase type 2 and express the CysLT(1) receptor. Eur. J. Biochem. 268 (2001) 2578-2586
32. Spanbroek R., Hildner M., Kohler A., Muller A., Zintl F., Kuhn H., Radmark O., Samuelsson B., and Habenicht A.J. IL-4 determines eicosanoid formation in dendritic cells by down-regulation of 5-lipoxygenase and up-regulation of 15-lipoxygenase 1 expression. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 5152-5157
33. Spanbroek R., Gräbner R., Lötzer K., Hildner M., Urbach A., Rühling K., Moos M.P.W., Kaiser B., Cohnert T.U., Wahlers T., Zieske A., Plenz G., Robenek H., Salbach P., Kühn H., Rådmark O., Samuelsson B., and Habenicht A.J.R. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 1238-1243
34. Stanke-Labesque F., Devillier P., Veitl S., Caron F., Cracowski J.L., and Bessard G. Cysteinyl leukotrienes are involved in angiotensin II-induced contraction of aorta from spontaneously hypertensive rats. Cardiovasc. Res. 49 (2001) 152-160
35. Stanke-Labesque F., Hardy G., Vergnaud S., Devillier P., Peoc'h M., Randon J., Bricca G., Caron F., Cracowski J.L., and Bessard G. Involvement of cysteinyl leukotrienes in angiotensin II-induced contraction in isolated aortas from transgenic (mRen-2)27 rats. J. Hypertens. 20 (2002) 263-272
36. Stanke-Labesque F., Hardy G., Caron F., Cracowski J.L., and Bessard G. Inhibition of leukotriene synthesis with MK-886 prevents a rise in blood pressure and reduces noradrenaline-evoked contraction in L-NAME-treated rats. Brit. J. Pharmacol. 140 (2003) 186-194
37. Vila L. Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: role in atherosclerosis. Med. Res. Rev. 24 (2004) 399-424
38. Werz O., and Steinhilber D. Selenium-dependent peroxidases suppress 5-lipoxygenase activity in B-lymphocytes and immature myeloid cells. The presence of peroxidase-insensitive 5-lipoxygenase activity in differentiated myeloid cells. Eur. J. Biochem. 242 (1996) 90-97
39. Werz O., Klemm J., Samuelsson B., and Rådmark O. 5-Lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 5261-5266
40. Werz O., Szellas D., Steinhilber D., and Rådmark O. Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPK-activated protein kinase 2 (MK2). J. Biol. Chem. 277 (2002) 14793-14800
41. Werz O., Bürkert E., Fischer L., Szellas D., Dishart D., Samuelsson B., et al. Extracellular signal-regulated kinases phosphorylate 5-lipoxygenase and stimulate 5-lipoxygenase product formation in leukocytes. Fed. Am. Soc. Exp. Biol. 16 (2002) 441-1443
42. Ye Y.N., Liu E.S., Shin V.Y., Wu W.K., Luo J.C., and Cho C.H. Nicotine promoted colon cancer growth via epidermal growth factor receptor, c-Src, and 5-lipoxygenase-mediated signal pathway. J. Pharmacol. Exp. Ther. 308 (2004) 66-72
43. Zeng Z.Z., Yellaturu C.R., Neeli I., and Rao G.N. 5(S)-hydroxyeicosatetraenoic acid stimulates DNA synthesis in human microvascular endothelial cells via activation of Jak/STAT and phosphatidylinositol 3-kinase/Akt signaling, leading to induction of expression of basic fibroblast growth factor 2. J. Biol. Chem. 277 (2002) 41213-41219
44. Zhao L., Moos M.P., Gräbner R., Pédrono F., Fan J., Kaiser B., John N., Schmidt S., Spanbroek R., Lötzer K., Huang L., Cui J., Rader D.J., Evans J.F., Habenicht A.J.R., and Funk C.D. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat. Med. 10 (2004) 966-973
45. Zukovska-Grojec Z., Bayorh M.A., Kopin I.J., and Feurstein G. Overall and regional hemodynamic effects of leukotriene D4 in spontaneously hypertensive rats. Hypertension 7 (1985) 507-513